Skip to main content
. Author manuscript; available in PMC: 2024 May 20.
Published in final edited form as: Clin Cancer Res. 2022 Feb 15;28(4):573–575. doi: 10.1158/1078-0432.CCR-21-3949

Figure 1.

Figure 1.

Graphical depiction of differential DNA damage response of DNMT3A-mutant leukemia (left) and DNMT3A wild-type leukemia (right) in response to cytarabine (Ara-C). While the wild-type leukemia cells are able to recruit PARP to repair single-strand DNA breaks, the DNMT3A-mutant leukemia is unable to do so. The result is DNA replication form collapse and increased sensitivity to the chemotherapeutic agent. Adapted from an image created with BioRender.com.